| S7093 |
IPA-3
|
IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).
|
-
Discov Oncol, 2025, 16(1):364
-
Nat Commun, 2024, 15(1):2989
-
Biomolecules, 2024, 14(2)237
|
|
| S7271 |
FRAX597
|
FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
|
-
BMC Biol, 2025, 23(1):166
-
J Cell Physiol, 2024, 10.1002/jcp.31291
-
Sci Rep, 2024, 14(1):4060
|
|
| S7094 |
PF-3758309
|
PF-03758309 (PF-03758309) is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4 with Kd of 2.7 nM. This compound is antiproliferative and induces apoptosis in a HCT116 tumour model.
|
-
Cell Commun Signal, 2025, 23(1):135
-
Nat Commun, 2024, 15(1):3178
-
Oncogene, 2023, 42(39):2878-2891
|
|
| S7807 |
FRAX486
|
FRAX486 is a potent p21-activated kinase (PAK) inhibitor with IC50 values of 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively.
|
-
iScience, 2023, 26(8):107333
-
Biochim Biophys Acta Mol Cell Res, 2022, 1869(8):119264
-
J Mol Cell Biol, 2021, 13(1):41-58
|
|
| S7989 |
FRAX1036
|
FRAX-1036 is a potent and selective PAK inhibitor with biochemical potency (Ki) of 23.3 nM and 72.4 nM against PAK1 and PAK2.
|
-
bioRxiv, 2023, 10.1101/2023.12.15.571909
-
Cell Rep, 2022, 41(1):111442
-
Nature, 2021, 595(7869):730-734
|
|
| S8264 |
NVS-PAK1-1
|
NVS-PAK1-1 is a potent and selective allosteric p21-activated kinase 1 (PAK1) inhibitor with an IC50 of 5 nM.
|
-
NPJ Breast Cancer, 2023, 9(1):48
-
J Med Chem, 2022, 65(23):15627-15641
|
|
| S1976 |
LCH-7749944
|
LCH-7749944 (GNF-PF-2356) is a novel and potent p21-activated kinase 4 (PAK4) inhibitor with an IC50 of 14.93 μM and has a less potent inhibitory effect against PAK1, PAK5 and PAK6. This compound causes successful inhibition of EGFR activity due to its inhibitory effect on PAK4.
|
-
J Exp Clin Cancer Res, 2025, 44(1):134
-
Endocrinology, 2023, 164(6)bqad073
|
|
| E2484 |
Hydrastine
|
Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine), a natural alkaloid present in Hydrastis canadensis, is an inhibitor of PAK4.
|
|
|
| S8139New |
G-5555
|
G-5555 is a selective inhibitor of Group I p21-activated kinases (PAKs), including PAK1, PAK2, and PAK3, with Ki values of 3.7 nM for PAK1 and 11 nM for PAK2.
|
|
|
| E2380 |
GNE 2861
|
GNE 2861, a PAK inhibitor that displays group II selectivity, inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively.
|
|
|
| S8032 |
PRT062607 (P505-15) HCl
|
PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
|
-
Sci Adv, 2025, 11(31):eadu4270
-
Sci Rep, 2024, 14(1):7739
-
J Exp Med, 2023, 220(9)e20230054
|
|
| S8444 |
Padnarsertib (KPT-9274, ATG-019)
|
Padnarsertib (KPT 9274) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.
|
-
Signal Transduct Target Ther, 2025, 10(1):222
-
Cell Rep Med, 2024, 5(2):101416
-
Sci Rep, 2023, 13(1):3334
|
|